Hormonal
GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.
For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.
Significant reductions in major adverse cardiovascular events (MACE) have been demonstrated with liraglutide (13%), semaglutide (26%), and dulaglutide (10%)... A cardiovascular outcome trial for tirzepatide in those with obesity but without diabetes is pending.
Why this rating
Based on large, long-term randomized controlled outcome trials (LEADER, SUSTAIN-6, SELECT).
Source
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Andrew-Hyun Lee et al. · Healthcare · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →